|
| Human Siglec-9 Protein (LTP10863) |
|
| LTP10863 |
|
| 100ug |
|
|
$406 In stock |
| Siglec-9 is a sialic-acid-binding lectin expressed predominantly on myeloid cells. Aberrant glycosylation occurs in essentially all types of cancers and results in increased sialylation. Thus, when the mucin MUC1 is expressed on cancer cells, it is decorated by multiple short, sialylated O-linked glycans (MUC1-ST). |
| Recombinant Human Siglec-9 Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Gln18-Gly348. |
|
| Siglec-9 |
|
| Human |
|
| Q9Y336 |
|
| Gln18-Gly348 |
|
| The protein has a predicted MW of 62.8 kDa. Due to glycosylation, the protein migrates to 80-110 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-hFc |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
